Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 671

Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA

Dr Ashkan Emadi speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a study looking at the combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

He explains that after conducting robust mechanisms of the transcriptome and translatome it was found that the combination of pegcrisantaspase and venetoclax significantly interferes with the initiation of protein translation in those cells.

Dr Emadi explains that when moving the study to the animal model, the combination arm was highly superior.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation